Related Experiment Video
Updated: Jun 13, 2026
10:10
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
Treating arthritis by immunomodulation: is there a role for regulatory T cells?
Ellen J Wehrens1, Femke van Wijk, Sarah T Roord
1Department of Pediatric Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht (UMCU), Lundlaan 6, 3584 EA, Utrecht, The Netherlands. e.j.m.wehrens@umcutrecht.nl
Rheumatology (Oxford, England)
|May 14, 2010
Summary
Regulatory T cells are crucial for controlling autoimmune responses, offering therapeutic potential for autoimmune arthritis. Combining strategies to enhance these cells may be the most effective clinical approach.
Area of Science:
- Immunology
- Rheumatology
- Cell Biology
Background:
- Regulatory T cells (Tregs) were discovered 15 years ago, opening a new research field.
- Tregs play a critical role in suppressing autoimmune responses.
- There is significant therapeutic potential for Tregs in treating autoimmune arthritis.
Purpose of the Study:
- To review recent studies on Tregs in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
- To investigate the presence, phenotype, and function of Tregs in RA and JIA patients.
- To consider the therapeutic potential of Tregs for autoimmune arthritis.
Main Methods:
- Review of recent scientific literature.
- Analysis of Treg presence, phenotype, and function in RA and JIA.
- Discussion of direct and indirect Treg-targeting strategies.
Main Results:
- Evidence highlights the critical role of Tregs in controlling autoimmune responses.
- Studies investigate Treg characteristics in RA and JIA patients.
- Various direct and indirect methods to target Tregs are being explored.
Conclusions:
- Regulatory T cells hold promise for autoimmune arthritis treatment.
- A combination of Treg-enhancing strategies may offer the most successful clinical application.
- Further research into Treg function and therapeutic targeting is warranted.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...